Vanda Pharmaceuticals Inc. – Filings and Transcripts

NASDAQ: VNDA
Share price (5/22/26): $6.19
Market cap (5/22/26): $372 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 03/31/26 Q1

ended 12/31/25 FY 2025

ended 09/30/25 Q3

ended 06/30/25 Q2

ended 03/31/25 Q1

Prospectuses and Registrations Filter

Shelf registration

Registration of securities for employees

Registration of securities on exchange – amended

Registration of securities for employees

Registration of securities on exchange – amended

Ownership Filter

Mitchell Stephen Ray

State Street Corporation

BlackRock Portfolio Management LLC

Duncan Charles Cliff

Duncan Charles Cliff

News Filter

Reports First Quarter 2026 Financial Results

Appoints Dr. Charles Duncan to Its Board of Directors

Change in Directors, Officers or Compensation

Material Disclosure

Announces FDA Approval of BYSANTITM (Milsaperidone) for the Treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Additional info about upcoming vote

Definitive proxy

Other Filter

Notice of effectiveness

Scanned paper annual report submission

Scanned paper annual report submission

Scanned paper annual report submission – amended

Scanned paper annual report submission